Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Radiology · Fibrocystic Breast Changes

Do BI-RADS 4 or 5 Require Biopsy With Fibrocystic Breasts?

At a Glance

Fibrocystic breast changes can cause familiar lumps, but they do not rule out cancer when imaging is suspicious. A BI-RADS 4 or 5 finding generally needs an image-guided biopsy, and the tissue result is compared with the images.

If diagnostic imaging assigns a finding BI-RADS 4 or BI-RADS 5, a biopsy is strongly recommended, even if you have a history of fibrocystic breast changes and the lump feels exactly like a familiar cyst [1][2]. It can be incredibly frustrating to hear that a familiar-feeling lump needs further testing, but a biopsy is the standard next step to determine exactly what the tissue is [3].

Why Imaging Outweighs How a Lump Feels

When you have fibrocystic breast changes, your breasts may naturally feel lumpy. Because of this, it can be confusing when a doctor recommends a biopsy for something that feels normal to you. However, medical studies show that a physical examination—simply feeling the lump—is not enough to safely eliminate the possibility of breast cancer [4]. Some cancerous lesions (areas of abnormal tissue) can mimic the smooth or firm feel of a cyst.

Imaging technologies like mammograms or ultrasounds look deeper. If the radiologist sees signs such as irregular shapes, spiculated margins (irregular, spike-like edges), or certain calcifications (tiny calcium deposits), these features may prompt a suspicious assessment [5][6]. A genuinely simple cyst is usually considered benign on ultrasound, but if it has a thick wall or solid components (making it a complex cyst), it may be flagged.

Understanding BI-RADS 4 and 5

BI-RADS (Breast Imaging Reporting and Data System) is a standardized reporting and assessment system used widely for breast imaging. A score of 4 or 5 is an assessment of the likelihood of malignancy (cancer) based on visual features [7], not a definitive diagnosis.

  • BI-RADS 4 (Suspicious Abnormality): This means the finding is suspicious enough that a biopsy is generally recommended [1]. Because this category is broad, it is broken down into population-level likelihood ranges:
    • 4A: Low suspicion (roughly a 2% to 10% chance) [7].
    • 4B: Moderate suspicion (roughly a 10% to 50% chance) [7].
    • 4C: High suspicion (roughly a 50% to 95% chance) [7].
  • BI-RADS 5 (Highly Suggestive of Malignancy): This means the area has classic imaging features of breast cancer, with an intended probability of 95% or higher [8].

Because actual rates vary based on age and the specific imaging methods used [9][10], tissue testing is strongly recommended to confirm a diagnosis before deciding on any next steps. Do not wait to see if the lump changes; it is best to contact your care team promptly to arrange the recommended follow-up.

What to Expect From a Biopsy

To find out exactly what the lump is, your doctor will likely recommend a biopsy to sample the tissue [11]. While an image-guided core needle biopsy (using a hollow needle guided by ultrasound or mammogram) is very common [3], other methods include vacuum-assisted or MRI-guided biopsies, or sometimes a surgical excision (removing the area with surgery) depending on the lesion.

Usually, a core needle biopsy is an outpatient procedure done with local anesthetic (numbing medicine). You may experience some bruising or soreness afterward. The doctor may also leave a tiny metal marker clip in the breast so the exact spot can be found on future scans. Results typically take a few days to a week.

The Role of Pathology and “Concordance”

A pathologist will examine the sampled tissue under a microscope to identify benign conditions (like fibrocystic changes), atypical cells (abnormal cells that aren’t cancer but may increase risk), or cancer [12][13].

Once the pathology report returns, your doctor and radiologist will check for radiology-pathology concordance [14]. They will ask: Does this biopsy result make sense given how suspicious the imaging looked?

  • Concordant: If the imaging looked somewhat like a complicated cyst and the biopsy confirms it is a fibrocystic change, the results are “concordant” (they match). Your doctor will then recommend a specific follow-up plan, which may be routine screening or short-term monitoring.
  • Discordant: If the imaging looked highly suspicious (like a BI-RADS 5) but the biopsy only shows normal tissue, the results are “discordant.” The doctor may suspect sampling error (the needle missed the target) and may recommend a repeat biopsy or surgical excision to be absolutely certain [15][16].

Common questions in this guide

Can fibrocystic breasts explain a BI-RADS 4 or 5 result without a biopsy?
Fibrocystic changes can cause lumps and cysts, but they do not make a suspicious imaging result safe to ignore. BI-RADS 4 or 5 findings generally require tissue sampling, even when the lump feels like a familiar cyst. Only the biopsy and follow-up review can determine whether the imaging and tissue results agree.
What is the difference between BI-RADS 4 and BI-RADS 5?
BI-RADS 4 means the finding is suspicious and a biopsy is generally recommended; 4A, 4B, and 4C represent increasing estimated likelihoods of cancer. BI-RADS 5 has imaging features strongly suggestive of cancer, with an intended likelihood of at least 95%. Neither category is a diagnosis until tissue is examined.
What biopsy is usually done for a suspicious breast finding?
An image-guided core needle biopsy is commonly used and is usually performed as an outpatient procedure with local numbing medicine. Ultrasound, mammography, or MRI may guide the needle, and vacuum-assisted biopsy or surgical removal may be considered in some situations.
What happens if the biopsy is benign after a BI-RADS 4 or 5 result?
The radiologist and pathologist compare the biopsy result with the imaging to decide whether they are concordant, meaning they explain each other. If a benign result does not account for a highly suspicious image, the team may recommend another biopsy or surgical excision because the needle may have missed the target.
Should I wait to see whether a BI-RADS 4 or 5 lump changes?
No. A BI-RADS 4 or 5 assessment warrants prompt contact with your care team to arrange the recommended biopsy or other follow-up, even if the lump feels familiar or changes over time. Do not use physical feel alone to rule out cancer.

Get notified when new evidence is published on breast fibrocystic disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    MRI in the Assessment of BI-RADS® 4 lesions.

    Leithner D, Wengert G, Helbich T, et al.

    Topics in magnetic resonance imaging : TMRI 2017; (26(5)):191-199 doi:10.1097/RMR.0000000000000138.

    PMID: 28961568
  2. 2

    Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text.

    Lavoué V, Fritel X, Antoine M, et al.

    European journal of obstetrics, gynecology, and reproductive biology 2016; (200()):16-23.

    PMID: 26967341
  3. 3

    Sonographic Characteristics and Pathology Correlation of Breast Imaging Reporting and Data System (BI-RADS) Category 4 Lesions.

    Khan P, Masroor I, Alam MS, et al.

    Cureus 2023; (15(12)):e51410 doi:10.7759/cureus.51410.

    PMID: 38292968
  4. 4

    [Exploring a non-inflammatory clinical breast mass: Clinical practice guidelines].

    Legendre G, Guilhen N, Nadeau C, et al.

    Journal de gynecologie, obstetrique et biologie de la reproduction 2015; (44(10)):904-12.

    PMID: 26541562
  5. 5

    Nonpalpable BI-RADS 4 breast lesions: sonographic findings and pathology correlation.

    Elverici E, Barça AN, Aktaş H, et al.

    Diagnostic and interventional radiology (Ankara, Turkey) 2015; (21(3)):189-94 doi:10.5152/dir.2014.14103.

    PMID: 25835079
  6. 6

    Diagnostic accuracy of digital breast tomosynthesis in combination with 2D mammography for the characterisation of mammographic abnormalities.

    Sanmugasiva VV, Ramli Hamid MT, Fadzli F, et al.

    Scientific reports 2020; (10(1)):20628 doi:10.1038/s41598-020-77456-6.

    PMID: 33244075
  7. 7

    Value of breast MRI omics features and clinical characteristics in Breast Imaging Reporting and Data System (BI-RADS) category 4 breast lesions: an analysis of radiomics-based diagnosis.

    Cui Q, Sun L, Zhang Y, et al.

    Annals of translational medicine 2021; (9(22)):1677 doi:10.21037/atm-21-5441.

    PMID: 34988186
  8. 8

    BI-RADS Category 5 Assessments at Diagnostic Breast Imaging:Outcomes Analysis Based on Lesion Descriptors.

    Yao MM, Joe BN, Sickles EA, Lee CS

    Academic radiology 2019; (26(8)):1048-1052 doi:10.1016/j.acra.2018.07.018.

    PMID: 30195413
  9. 9

    The Utility of the Fifth Edition of the BI-RADS Ultrasound Lexicon in Category 4 Breast Lesions: A Prospective Multicenter Study in China.

    Gu Y, Tian JW, Ran HT, et al.

    Academic radiology 2022; (29 Suppl 1()):S26-S34 doi:10.1016/j.acra.2020.06.027.

    PMID: 32768352
  10. 10

    Does patient age affect the PPV3 of ACR BI-RADS Ultrasound categories 4 and 5 in the diagnostic setting?

    Hu Y, Yang Y, Gu R, et al.

    European radiology 2018; (28(6)):2492-2498 doi:10.1007/s00330-017-5203-3.

    PMID: 29302783
  11. 11

    Histopathological Correlation of Breast Carcinoma with Breast Imaging-Reporting and Data System.

    Aziz S, Mohamad MA, Md Zin RR

    The Malaysian journal of medical sciences : MJMS 2022; (29(4)):65-74 doi:10.21315/mjms2022.29.4.7.

    PMID: 36101539
  12. 12

    Diagnostic value of breast ultrasound in mammography BI-RADS 0 and clinically indeterminate or suspicious of malignancy breast lesions.

    Dobrosavljević A, Rakić S, Nikoli B, et al.

    Vojnosanitetski pregled 2016; (73(3)):239-45 doi:10.2298/vsp140508001d.

    PMID: 27295907
  13. 13

    The Evolving Role of Vacuum Assisted Biopsy of the Breast: A Progression from Fine-Needle Aspiration Biopsy.

    Bennett IC, Saboo A

    World journal of surgery 2019; (43(4)):1054-1061 doi:10.1007/s00268-018-04892-x.

    PMID: 30617562
  14. 14

    Pathologic High-risk Lesions, Diagnosis and Management.

    Murray M

    Clinical obstetrics and gynecology 2016; (59(4)):727-732 doi:10.1097/GRF.0000000000000234.

    PMID: 27681693
  15. 15

    Idiopathic Granulomatous Mastitis in a Postmenopausal Woman Mimicking Breast Carcinoma: A Diagnostic Challenge.

    Xanthopoulou G, Solakis E, Barkolias C, et al.

    Cureus 2026; (18(3)):e106027 doi:10.7759/cureus.106027.

    PMID: 42051828
  16. 16

    Correlations Between Core Needle Biopsy and Excisional Biopsy Findings in Suspected Breast Lesions: A Single Center Study.

    Davidson T, Ravid MM, Nissan E, et al.

    The Israel Medical Association journal : IMAJ 2018; (20(7)):401-404.

    PMID: 30109786

This page is for informational purposes only and does not constitute medical advice. It explains why BI-RADS 4 or 5 findings are usually evaluated with biopsy despite fibrocystic breast changes; your radiologist or breast care team should interpret your results and timing.